FDA highlights its research findings on BPA at the Sept 13 FDA Grand Rounds

	FDA spotlights its research findings on BPA  Register today for FDA’s Sept. 13 Grand Rounds and receive CE credit

Thursday, September 13, 2018 12:00 p.m. - 1:00 p.m. EST Register here for webcast (public attendees and FDA staff) Presented by  K. Barry Delclos, Ph.D. Research Pharmacologist Division of Biochemical Toxicology FDA’s National Center for Toxicological Research What you’ll learn from this FDA Research Pharmacologist: The purpose of the BPA research program conducted by FDA and the NIEHS/NTP. The results of BPA pharmacokinetic studies and how these are combined with human exposure data in physiologically based pharmacokinetic models to predict internal exposures to BPA in humans exposed through food contact materials. The results of BPA rat toxicology studies conducted over a broad dose range and how all of these data can contribute to assessing BPA safety in humans. About the Presentation Bisphenol A, better known as BPA, is an industrial chemical used in producing polycarbonate plastics and epoxy resins used in consumer products like storage containers for foods and beverages, medical devices, and thermal paper.  Consumers are mainly exposed to BPA through food containers and there has been much controversy as to the potential toxicity of this BPA exposure.   FDA’s National Center for Toxicological Research and the National Institute of Environmental Health Sciences (NIEHS)/National Toxicology Program (NTP) have conducted a series of studies in the past decade to address data gaps identified by the FDA Science Board and NTP.   Results of the NCTR toxicity studies indicated that BPA produced adverse effects at high doses, but not at the low end of the dose range tested, consistent with its activity as a weak estrogen.  These results will inform ongoing BPA safety assessments, a topic of considerable public interest.